Adventitial Delivery of an Allogeneic Bone Marrow–Derived Adherent Stem Cell in Acute Myocardial Infarction

Rationale:MultiStem is an allogeneic bone marrow–derived adherent adult stem cell product that has shown efficacy in preclinical models of acute myocardial infarction (AMI). In this phase I clinical trial in patients with first ST-elevation–myocardial infarction (STEMI), we combine first-in-man delivery of MultiStem with a first-in-coronary adventitial delivery system to determine the effects of this system on left ventricular function at 4 months after AMI. Objective:Test the effects of adventitial delivery of Multistem in the peri-infarct period in patients with first STEMI. Methods and Results:This study was a phase I, open-label, dose-escalating registry control group study. Nineteen patients received MultiStem (20 million, n=6; 50 million, n=7; or 100 million, n=6) and 6 subjects were assigned to the registry control group. Two to 5 days after AMI, we delivered MultiStem to the adventitia of the infarct-related vessel in patients with first-time STEMI. All patients underwent primary percutaneous coro...